|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Hepatitis
|
2015
|
NIAID
|
4R37AI047365-16
|
|
Structure and Function of the Hepatitis C Virus Genome
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$458,399
|
|
Hepatitis
|
2015
|
NIDDK
|
5K24DK092336-04
|
|
Patient-oriented and effectiveness research in chronic liver disease
|
KIM, W. RAY
|
STANFORD UNIVERSITY
|
CA
|
$124,529
|
|
Hepatitis
|
2015
|
NIDDK
|
2R01DK041876-27
|
|
Mechanisms of Liver Cell Injury
|
GORES, GREGORY
|
MAYO CLINIC ROCHESTER
|
MN
|
$357,750
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI095097-04
|
|
HIV co-infection and HCV-induced liver fibrosis in vivo
|
SU, LISHAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$370,000
|
|
Hepatitis
|
2015
|
NIDDK
|
1P30DK097948-01A1
|
5072
|
Biorepository Core
|
FIOCCHI, CLAUDIO
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$221,916
|
|
Hepatitis
|
2015
|
NIAAA
|
1R21AA022720-01A1
|
|
BMAL1: A Novel Regulator For Inflammatory Liver Injury
|
YIN, LEI
|
UNIVERSITY OF MICHIGAN
|
MI
|
$184,261
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA035146-03
|
|
HIV, HCV and STI Risk Associated with Nonmedical Use of Prescription Opioids
|
MATEU-GELABERT, PEDRO
|
NATIONAL DEVELOPMENT & RES INSTITUTES
|
NY
|
$580,906
|
|
Hepatitis
|
2015
|
NICHD
|
5R01HD062489-05
|
|
Pediatric Adverse Drug Reactions in NASH
|
CHERRINGTON, NATHAN
|
UNIVERSITY OF ARIZONA
|
AZ
|
$313,889
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI104494-02
|
|
A screen for antiviral compounds targeting the Hepatitis B Virus ribonuclease H
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$337,500
|
|
Hepatitis
|
2015
|
NIMHD
|
5R24MD008095-03
|
|
Reducing Asian Hepatitis B Disparities through Health Information Technology
|
WEIR, ROSY
|
ASSOCIATION/ASIAN PACIFIC CMTY HLTH ORGS
|
CA
|
$291,991
|
|
Hepatitis
|
2015
|
NIAID
|
5K22AI100935-02
|
|
Innate immune regulation during hepatitis C virus infection
|
HORNER, STACY
|
DUKE UNIVERSITY
|
NC
|
$108,000
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI050611-11
|
|
A chicken model to study hepatitis E virus pathogenesis
|
MENG, XIANG-JIN
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$394,247
|
|
Hepatitis
|
2015
|
NIAID
|
5UM1AI068632-09
|
|
LOC-IMPAACT Leadership Group
|
NACHMAN, SHARON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$20,140,230
|
|
Hepatitis
|
2015
|
NICHD
|
5UM1AI068632-09
|
|
LOC-IMPAACT Leadership Group
|
NACHMAN, SHARON
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$4,390,488
|
|
Hepatitis
|
2015
|
NCI
|
5UM1AI068636-09
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
|
KURITZKES, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,000,000
|
|
Hepatitis
|
2015
|
NIAID
|
5UM1AI068636-09
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
|
KURITZKES, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$42,646,161
|
|
Hepatitis
|
2015
|
NIDA
|
5UM1AI068636-09
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
|
KURITZKES, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,727,032
|
|
Hepatitis
|
2015
|
NINDS
|
5UM1AI068636-09
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
|
KURITZKES, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$1,000,000
|
|
Hepatitis
|
2015
|
OD
|
5UM1AI068636-09
|
|
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
|
KURITZKES, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$545,000
|
|
Hepatitis
|
2015
|
NHLBI
|
5R21HL121740-02
|
|
The Risk of Transfusion Transmission of Hepatitis E Virus
|
NELSON, KENRAD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$159,846
|
|
Hepatitis
|
2015
|
NIAID
|
5UM1AI069418-09
|
|
Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit
|
LENNOX, JEFFREY
|
EMORY UNIVERSITY
|
GA
|
$1,977,185
|
|
Hepatitis
|
2015
|
NIAID
|
5UM1AI069503-09
|
|
Terry Beirn CPCRA Clinical Trials Unit
|
GORDIN, FRED
|
GEORGE WASHINGTON UNIVERSITY
|
DC
|
$1,055,836
|
|
Hepatitis
|
2015
|
NIAID
|
5UM1AI069536-09
|
|
HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)
|
SPECTOR, STEPHEN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$2,046,978
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI104887-03
|
|
Control of Viral Pathogenesis by Regulation of 2-5A Levels
|
WEISS, SUSAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$713,295
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK090794-05
|
|
Heat Shock Protein Synthesis Inhibitor Treatment of Hepatitis C Viral Infection
|
FRENCH, SAMUEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$334,950
|
|
Hepatitis
|
2015
|
NIAID
|
5R21AI109791-02
|
|
HCV biology and inhibition visualized at the single molecule level
|
WALTER, NILS
|
UNIVERSITY OF MICHIGAN
|
MI
|
$194,375
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI108765-02
|
|
Novel regulatory mechanisms control IFNL3 expression during HCV infection
|
SAVAN, RAM
|
UNIVERSITY OF WASHINGTON
|
WA
|
$435,000
|
|
Hepatitis
|
2015
|
NIAID
|
5R21AI107631-02
|
|
Study of rodent HCV-GBV like viruses
|
KAPOOR, AMIT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$237,288
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK087977-05
|
|
The Role of Mitochondrial Dysfunction in Non-Alcoholic Fatty Liver Disease
|
BROWNING, JEFFREY
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$366,541
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021838-03
|
|
Transcriptomics of Liver in Alcoholic Hepatitis
|
NORDEN-KRICHMAR, TRINA
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$256,060
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021898-03
|
|
ALCOHOLIC HEPATITIS PATHOGENESIS AS DETERMINED FROM HUMAN LIVER TISSUE ANALYSIS
|
FRENCH, SAMUEL
|
LA BIOMED RES INST/ HARBOR UCLA MED CTR
|
CA
|
$203,818
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK090313-05
|
|
Hepatic Steatosis and ER Stress-Inducible Transcription Factor CREBH
|
ZHANG, KEZHONG
|
WAYNE STATE UNIVERSITY
|
MI
|
$330,600
|
|
Hepatitis
|
2015
|
NIAID
|
5K08AI102761-03
|
|
Mechanisms of Neutralizing Antibody Resistance in Chronic HCV and HIV Infection
|
BAILEY, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$185,121
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI069000-10
|
|
Roles for microRNA-122 in hepatitis C virus RNA amplification
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$393,160
|
|
Hepatitis
|
2015
|
NHLBI
|
5K01HL121010-02
|
|
The role of CD8+ T cells in the development of Nonalcoholic Fatty Liver Disease
|
KENNEDY, ARION
|
VANDERBILT UNIVERSITY
|
TN
|
$113,004
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI105035-03
|
|
CD4+ T Cells in Acute Versus Chronic HCV Infection
|
LAUER, GEORG
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$543,750
|
|
Hepatitis
|
2015
|
NIGMS
|
5F31GM103259-03
|
|
HCV protease: from atomic mechanism for drug resistance to novel drug design
|
SOUMANA, DJADE
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$29,634
|
|
Hepatitis
|
2015
|
NIGMS
|
5R01GM100071-04
|
|
Nanofluidic Devices for Studying Assembly of Single Virus Particles
|
JACOBSON, STEPHEN
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$293,619
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI070101-09
|
|
Mechanisms of hepatitis C virus persistence
|
GRAKOUI, ARASH
|
EMORY UNIVERSITY
|
GA
|
$440,000
|
|
Hepatitis
|
2015
|
NIDA
|
5K23DA031612-04
|
|
Supporting Health in Drug Treatment Court for Women with HIV or Hepatitis C
|
MORSE, DIANE
|
UNIVERSITY OF ROCHESTER
|
NY
|
$172,275
|
|
Hepatitis
|
2015
|
NIAID
|
1R01AI110358-01A1
|
|
Mechanisms of HCV Assembly
|
YI, MINKYUNG
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$387,500
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK077704-07
|
|
Viral Hepatitis C and Lipid Homeostasis
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$337,125
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI096882-04
|
|
Persistent hepatitis C virus replication and T cell immunity in pregnancy
|
WALKER, CHRISTOPHER
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$584,545
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI099506-02
|
|
Modulation of internal ribosome entry by ribosomal protein RPS25
|
SARNOW, PETER
|
STANFORD UNIVERSITY
|
CA
|
$578,185
|
|
Hepatitis
|
2015
|
NIAAA
|
5P50AA011999-17
|
8467
|
Functional Dissection of EtOH-med Self-renew of Liver Tumor-Int Cells via TLR4
|
MACHIDA, KEIGO
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$198,195
|
|
Hepatitis
|
2015
|
NIAID
|
5F32AI106178-03
|
|
Mechanistic Studies of the Function of Desmosterol Homeostasis in HCV Replication
|
VILLAREAL, VALERIE ANNE
|
HARVARD MEDICAL SCHOOL
|
MA
|
$57,962
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK099055-02
|
|
Role of HIV-1 Nef in Acceleration of HCV-Mediated Liver Disease
|
PARK, IN-WOO
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
TX
|
$336,086
|
|
Hepatitis
|
2015
|
NIAID
|
1R01AI114748-01
|
|
miRNA-mediated premature T cell aging in vaccine failure during viral infection
|
YAO, ZHI
|
EAST TENNESSEE STATE UNIVERSITY
|
TN
|
$365,000
|
|
Hepatitis
|
2015
|
NCI
|
1R01CA190678-01
|
|
Mechanisms of obesity-induced hepatocarcinogenesis
|
CHUNG, FUNG-LUNG
|
GEORGETOWN UNIVERSITY
|
DC
|
$381,691
|
|
Hepatitis
|
2015
|
NHLBI
|
1R01HL119830-01A1
|
|
TTC39B in Metabolism
|
TALL, ALAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$400,000
|
|
Hepatitis
|
2015
|
NCI
|
1R01CA190776-01
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$666,229
|
|
Hepatitis
|
2015
|
NICHD
|
5R01HD075549-02
|
|
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
|
ROSEN, HUGO
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$313,134
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI097318-05
|
|
Underlying Mechanisms of ApoE in HCV Infection and Assembly
|
LUO, GUANGXIANG
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$367,500
|
|
Hepatitis
|
2015
|
NIDDK
|
5K23DK085150-05
|
|
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links
|
SUNDARAM, SHIKHA
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$175,494
|
|
Hepatitis
|
2015
|
NCI
|
1K99CA191152-01
|
|
Development of mosaic mouse models of HCC for genetic interspecies inference
|
FONT-BURGADA, JOAN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$109,620
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA012568-17
|
|
INCIDENCE OF HIV INFECTION IN A COHORT OF IV DRUG USERS
|
MEHTA, SHRUTI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1,226,902
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI106005-02
|
|
Dissecting virus neutralizing determinants to guide HCV vaccine development
|
LAW, MANSUN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$450,000
|
|
Hepatitis
|
2015
|
NIDDK
|
5K08DK101754-02
|
|
New Hepatocyte Model Systems to study Hepatitis B Virus Infection
|
SCHWARTZ, ROBERT
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$153,457
|
|
Hepatitis
|
2015
|
NIAID
|
1R21AI115476-01
|
|
T cell responses at the site of infection
|
LAUER, GEORG
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$261,000
|
|
Hepatitis
|
2015
|
NIAID
|
1R03AI115171-01
|
|
Exploring HCV infection in engineered cultures of iPSC-derived human liver cells
|
KHETANI, SALMAN
|
COLORADO STATE UNIVERSITY
|
CO
|
$48,645
|
|
Hepatitis
|
2015
|
NCI
|
5R21CA185707-02
|
|
Tethered Cationic Lipoplex Nanoparticle Assay for Liver Cancer Detection and Surv
|
LEE, LY
|
OHIO STATE UNIVERSITY
|
OH
|
$159,393
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI097552-02
|
|
Role of Lipid Droplets in Hepatitis C Virus Infection
|
OTT, MELANIE
|
J. DAVID GLADSTONE INSTITUTES
|
CA
|
$477,500
|
|
Hepatitis
|
2015
|
NIDA
|
5K01DA036452-02
|
|
Social Networks of Youth who Misuse Prescription Opioids and Risk for HIV/HCV
|
AL-TAYYIB, ALIA
|
DENVER HEALTH AND HOSPITAL AUTHORITY
|
CO
|
$151,618
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA035736-03
|
|
CYP2D6 Genotype and Cognitive Deficits in Methamphetamine Users with/without HIV
|
CHERNER, MARIANA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$333,369
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI091707-05
|
|
Type I interferon-stimulated genes and the antiviral immune response
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$422,500
|
|
Hepatitis
|
2015
|
NIEHS
|
5R01ES021375-04
|
|
PCBs worsen obesity/metabolic syndrome through 'toxic metabolic endotoxemia'
|
CAVE, MATTHEW
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$337,500
|
|
Hepatitis
|
2015
|
NIAAA
|
5R01AA012863-15
|
|
Mechanisms of Liver Injury by Hepatitis C and Alcohol
|
WEINMAN, STEVEN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$501,081
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI100748-04
|
|
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV Coinfection
|
BHATTACHARYA, DEBIKA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$386,315
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK088114-05
|
|
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
|
ORAL, ELIF
|
UNIVERSITY OF MICHIGAN
|
MI
|
$338,213
|
|
Hepatitis
|
2015
|
NIGMS
|
5R01GM104503-05
|
|
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
|
BUOLAMWINI, JOHN
|
ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
|
IL
|
$244,241
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109965-02
|
5820
|
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
|
TING, JENNY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$414,750
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109965-02
|
5821
|
Novel Pathogen Recognition Pathways and Control of Hepatitis A Virus
|
LEMON, STANLEY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$408,220
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109965-02
|
5825
|
Protein Purification and Biochemistry
|
DUNCAN, JOSEPH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$328,604
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI111970-02
|
|
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models
|
BROWN, ASHLEY
|
UNIVERSITY OF FLORIDA
|
FL
|
$1,127,672
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA025885-07
|
|
Sustainable HIV Risk Reduction Strategies for CJ Systems
|
LEHMAN, WAYNE
|
TEXAS CHRISTIAN UNIVERSITY
|
TX
|
$554,460
|
|
Hepatitis
|
2015
|
NIDDK
|
2R01DK074932-09
|
|
LDL Receptor Related Protein-1 in Metabolic and Cardiovascular Disease
|
HUI, DAVID
|
UNIVERSITY OF CINCINNATI
|
OH
|
$355,969
|
|
Hepatitis
|
2015
|
NIDDK
|
5K01DK095031-05
|
|
Interactions between type I and III interferon during resolution of HCV infection
|
SCHOGGINS, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$102,087
|
|
Hepatitis
|
2015
|
NICHD
|
2R01HD041230-11
|
|
Prenatal Metabolic Porgramming of the Offspring
|
DEVASKAR, SHERIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$319,550
|
|
Hepatitis
|
2015
|
NIDDK
|
1R01DK101941-01A1
|
|
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
|
GARG, ABHIMANYU
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$363,375
|
|
Hepatitis
|
2015
|
NIAID
|
1R01AI110577-01A1
|
|
Dynamics of Hepatis C viral RNA-dependent RNA replication
|
JOHNSON, KENNETH
|
UNIVERSITY OF TEXAS, AUSTIN
|
TX
|
$479,012
|
|
Hepatitis
|
2015
|
NIDDK
|
5K23DK090209-04
|
|
Gender and hormonal influences on liver fibrosis after transplant for hepatitis C
|
FORDE, KIMBERLY
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$182,110
|
|
Hepatitis
|
2015
|
NIGMS
|
5P41GM103314-42
|
|
National Resource for Mass Spectrom of Biological Macromolecules
|
CHAIT, BRIAN
|
ROCKEFELLER UNIVERSITY
|
NY
|
$1,468,072
|
|
Hepatitis
|
2015
|
NIMH
|
5K01MH097847-03
|
|
An Exercise Intervention to Prevent Interferon-Induced Depression in Hepatitis C
|
RETHORST, CHAD
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$148,640
|
|
Hepatitis
|
2015
|
NIMHD
|
5R24MD002756-08
|
|
Dissemination of an Evidence-based HepB Intervention to Korean Churches
|
MA, GRACE
|
TEMPLE UNIV OF THE COMMONWEALTH
|
PA
|
$458,425
|
|
Hepatitis
|
2015
|
NIDDK
|
5K23DK095707-03
|
|
An Assessment of Liver Disease in HIV-infected and HIV/HBV Co-infected Tanzanians
|
HAWKINS, CLAUDIA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$126,865
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI099245-04
|
|
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets
|
GLENN, JEFFREY
|
STANFORD UNIVERSITY
|
CA
|
$1,027,579
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA033871-03
|
|
Action Plans & Memory Consolidation: Reducing HIV Risk in Drug Users
|
STACY, ALAN
|
CLAREMONT GRADUATE UNIVERSITY
|
CA
|
$397,018
|
|
Hepatitis
|
2015
|
NIDA
|
5K24DA035684-02
|
|
Treatment outcomes and comorbidity in HIV-infected IDU
|
LUCAS, GREGORY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$168,171
|
|
Hepatitis
|
2015
|
NIDDK
|
1K08DK099412-01A1
|
|
The role of macrophage migration inhibitory factor in autoimmune hepatitis
|
ASSIS, DAVID
|
YALE UNIVERSITY
|
CT
|
$152,874
|
|
Hepatitis
|
2015
|
NIDA
|
5K24DA034621-04
|
|
Patient Oriented Research in Hepatitis C-infected Injection Drug Users
|
SULKOWSKI, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$118,638
|
|
Hepatitis
|
2015
|
NIDDK
|
7R01DK085252-05
|
|
LPS binding to TLR4 regulates hepatic stellate cell activation and fibrosis
|
SEKI, EKIHIRO
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$369,750
|
|
Hepatitis
|
2015
|
NIAID
|
5K08AI097322-04
|
|
Antivirals for Hepatitis C Targeting Phosphoinositide Metabolism
|
GELMAN, MICHAEL
|
STANFORD UNIVERSITY
|
CA
|
$133,191
|
|
Hepatitis
|
2015
|
NIAID
|
5R03AI109460-02
|
|
Hepatitis B Virus diversity and ribonuclease H inhibitor efficacy
|
TAVIS, JOHN
|
SAINT LOUIS UNIVERSITY
|
MO
|
$75,750
|
|
Hepatitis
|
2015
|
NIAID
|
1R21AI107252-01A1
|
|
Anti-HBV therapeutics based on rare-cutting targeted endonucleases
|
JEROME, KEITH
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$203,715
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI095690-05
|
|
Micro-RNA 122 and Chronic Hepatitis C
|
LEMON, STANLEY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$368,389
|
|
Hepatitis
|
2015
|
NIDDK
|
5K08DK101757-02
|
|
Optimization and control of hepatocyte activity via biofunctional modification
|
WERTHEIM, JASON
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$151,311
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI094409-05
|
|
Antisense Mediated Treatment of Hepatitis B Virus Infection
|
GARAIGORTA, URTZI
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$768,816
|
|
Hepatitis
|
2015
|
NIAID
|
1U01AI115711-01
|
|
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant
|
GRINSPOON, STEVEN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$587,655
|
|
Hepatitis
|
2015
|
NIAID
|
1U01AI115714-01
|
|
Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant
|
STOCK, PETER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$601,291
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA164029-04
|
|
Murine Model of HCV-Associated Human Liver Cancer
|
LEMON, STANLEY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$470,695
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK097374-03
|
|
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
|
TAI, ANDREW
|
UNIVERSITY OF MICHIGAN
|
MI
|
$338,213
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA166213-04
|
|
Super-infection and virus spread during chronic hepadnaviral infection
|
GUDIMA, SEVERIN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$319,945
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI009484-46
|
|
Pathogenesis of Persistent Viral Infection
|
OLDSTONE, MICHAEL
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$473,750
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI072613-09
|
|
Identification and characterization of cellular factors involved in HCV entry
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$546,673
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI094469-05
|
|
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
|
IYER, RADHAKRISHNAN
|
SPRING BANK TECHNOLOGIES, INC.
|
MA
|
$901,490
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA163805-05
|
|
Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans
|
JUON, HEE-SOON
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$189,113
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI111825-02
|
7689
|
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$632,104
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA158271-04
|
|
Hepatocyte Nox proteins in the pathogenesis of hepatocellular carcinoma
|
CHOI, JINAH
|
UNIVERSITY OF CALIFORNIA, MERCED
|
CA
|
$276,582
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA168912-02
|
|
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
|
HE, YUKAI
|
GEORGIA REGENTS UNIVERSITY
|
GA
|
$319,966
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK093526-04
|
|
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection
|
YAO, ZHI
|
EAST TENNESSEE STATE UNIVERSITY
|
TN
|
$317,550
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA161694-04
|
|
Aflatoxin B1 hepatocarcinogenesis in the mGSTA3-/- mouse
|
SELL, STEWART
|
WADSWORTH CENTER
|
NY
|
$292,725
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI099284-04
|
|
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance
|
RICE, CHARLES
|
ROCKEFELLER UNIVERSITY
|
NY
|
$735,361
|
|
Hepatitis
|
2015
|
NHLBI
|
5R01HL105704-05
|
|
Broad Detection of Infectious Agents in Blood by Microarrays and Deep Sequencing
|
CHIU, CHARLES
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$573,600
|
|
Hepatitis
|
2015
|
NIDDK
|
1R01DK102597-01A1
|
|
NAFLD: Mechanisms and Treatments
|
TIMCHENKO, NIKOLAI
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$346,630
|
|
Hepatitis
|
2015
|
NIAID
|
5R21AI111250-02
|
|
Function of Lipid Droplets in Viral Entry and Membrane Fusion
|
TANG, HENGLI
|
FLORIDA STATE UNIVERSITY
|
FL
|
$181,384
|
|
Hepatitis
|
2015
|
NIDDK
|
7R01DK088940-05
|
|
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease
|
THYFAULT, JOHN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$283,125
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK095862-03
|
|
Protective role of adenosine 2A receptor in NAFLD
|
WU, CHAODONG
|
TEXAS A&M AGRILIFE RESEARCH
|
TX
|
$317,242
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK096076-03
|
|
Role of Dab2 in Fatty Liver Disease
|
LEITINGER, NORBERT
|
UNIVERSITY OF VIRGINIA
|
VA
|
$343,650
|
|
Hepatitis
|
2015
|
NIGMS
|
5R01GM064803-11
|
|
Genome-Scale Analysis of RNA Virus Tertiary Structure
|
WEEKS, KEVIN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$317,677
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA033777-04
|
|
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
|
MARKOWITZ, MARTIN
|
AARON DIAMOND AIDS RESEARCH CENTER
|
NY
|
$916,984
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK098655-03
|
|
Hepatic insulin resistance and metabolic disease
|
WHITE, MORRIS
|
CHILDREN'S HOSPITAL CORPORATION
|
MA
|
$459,892
|
|
Hepatitis
|
2015
|
NCI
|
5R03CA186203-02
|
|
Investigating the cause of racial/ethnic disparity in hepatocellular cancer risk
|
SETIAWAN, VERONICA
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$82,438
|
|
Hepatitis
|
2015
|
NCI
|
1F32CA192633-01
|
|
Disruption of the Host DNA Damage Response by Hepatitis C Virus
|
MITCHELL, JONATHAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$52,406
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI057229-12
|
7617
|
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination
|
DAVIS, MARK
|
STANFORD UNIVERSITY
|
CA
|
$265,955
|
|
Hepatitis
|
2015
|
NIEHS
|
1F30ES025099-01
|
|
Xenobiotic Receptors Modulate PCB-induced Steatohepatitis
|
CLAIR, HEATHER
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$33,854
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI094474-06
|
|
Development of a novel drug candidate that inhibits hepatitis B virus covalently
|
GUO, HAITAO
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$686,525
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI052447-13
|
|
Gene Silencing as an Antiviral Defense in Animal Cells
|
DING, SHOU-WEI
|
UNIVERSITY OF CALIFORNIA RIVERSIDE
|
CA
|
$505,177
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA086978-12
|
|
Molecular mechanism of diet-induced carcinogenesis
|
JACOB, SAMSON
|
OHIO STATE UNIVERSITY
|
OH
|
$311,850
|
|
Hepatitis
|
2015
|
NIDA
|
5K24DA037034-02
|
|
Mentoring and Empowerment in the Context of HIV Care for At-Risk Populations
|
JOHNSON, MALLORY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$183,707
|
|
Hepatitis
|
2015
|
NCI
|
1R01CA186566-01A1
|
|
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)
|
HASSAN, MANAL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$832,002
|
|
Hepatitis
|
2015
|
NCI
|
9R01CA193244-05A1
|
|
Role of microR-122 in Hepatocarcinogenesis using Conditional Knockout Mice
|
GHOSHAL, KALPANA
|
OHIO STATE UNIVERSITY
|
OH
|
$375,706
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA016078-14
|
|
The Progression of Hepatitis C Among IDUs with HIV
|
BALAGOPAL, ASHWIN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$703,923
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA031056-06
|
|
International Collaborative of prospective studies of HIV and Hepatitis in IDU
|
PAGE, KIMBERLY
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
NM
|
$386,153
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK101579-03
|
|
Physiology of Lipid Droplets and Triglyceride Storage
|
FARESE, ROBERT
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$589,475
|
|
Hepatitis
|
2015
|
NIGMS
|
5R37GM056207-20
|
|
Simulation of Proton and Hydride Transfer in Enzymes
|
HAMMES-SCHIFFER, SHARON
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
IL
|
$289,129
|
|
Hepatitis
|
2015
|
NCI
|
5R21CA183615-02
|
|
Functional Profiles of Hepatitis C Virus Genome at Single Nucleotide Resolution
|
SUN, REN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$200,970
|
|
Hepatitis
|
2015
|
NCI
|
5R21CA183954-02
|
|
A novel mediator of obesity associated hepatocellular carcinoma (HCC)
|
SARKAR, DEVANAND
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$165,844
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA034637-03
|
|
Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics
|
HAGAN, HOLLY
|
NEW YORK UNIVERSITY
|
NY
|
$667,893
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK095962-03
|
|
Novel therapeutic approaches to treating chronic hepatitis B virus infection
|
SU, LISHAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$551,970
|
|
Hepatitis
|
2015
|
NIAAA
|
5R37AA009300-20
|
|
Lipid Aldehyde and Ethanol Induced Liver Damage
|
PETERSEN, DENNIS
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$465,533
|
|
Hepatitis
|
2015
|
NIGMS
|
5R01GM105414-03
|
|
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV
|
BLACKARD, JASON
|
UNIVERSITY OF CINCINNATI
|
OH
|
$295,471
|
|
Hepatitis
|
2015
|
NCI
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$42,319
|
|
Hepatitis
|
2015
|
NHLBI
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$35,168
|
|
Hepatitis
|
2015
|
NIA
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$3,445
|
|
Hepatitis
|
2015
|
NIAID
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$219,204
|
|
Hepatitis
|
2015
|
NICHD
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$16,009
|
|
Hepatitis
|
2015
|
NIDA
|
5P30AI094189-04
|
5955
|
Clinical
|
CHAISSON, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$26,425
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA022177-09
|
|
Opioids, HIV/HCV and host cell innate immunity
|
HO, WENZHE
|
TEMPLE UNIV OF THE COMMONWEALTH
|
PA
|
$234,774
|
|
Hepatitis
|
2015
|
NHLBI
|
5R01HL119485-02
|
|
Novel viruses and viral dynamics in multiple transfusion recipients
|
KAPOOR, AMIT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$398,816
|
|
Hepatitis
|
2015
|
NIDA
|
1R21DA039010-01
|
|
Emotion Dysregulation and Risky Behavior Among People Who Inject Drugs
|
MACKESY-AMITI, MARY
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$238,683
|
|
Hepatitis
|
2015
|
NCI
|
5P01CA022443-38
|
6854
|
Mechanisms of Hepatitis B Virus Replication
|
LOEB, DANIEL
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$324,758
|
|
Hepatitis
|
2015
|
NCI
|
5P01CA022443-38
|
6867
|
Instrumentation
|
LOEB, DANIEL
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$68,573
|
|
Hepatitis
|
2015
|
NCI
|
5P01CA022443-38
|
6868
|
Virus Production
|
MERTZ, JANET
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$101,776
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA089121-09
|
|
Hepatitis C Virus and Hepatocellular Carcinoma
|
DASH, SRIKANTA
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$237,038
|
|
Hepatitis
|
2015
|
NIDA
|
2R01DA027379-04
|
|
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
|
SCHACKMAN, BRUCE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$522,235
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA031059-04
|
|
Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care
|
LINAS, BENJAMIN
|
BOSTON MEDICAL CENTER
|
MA
|
$612,390
|
|
Hepatitis
|
2015
|
NIAAA
|
1K23AA023753-01
|
|
Understanding and intervening with heavy drinking among patients with HIV and HCV
|
ELLIOTT, JENNIFER
|
NEW YORK STATE PSYCHIATRIC INSTITUTE
|
NY
|
$186,192
|
|
Hepatitis
|
2015
|
NIDA
|
1R34DA038530-01A1
|
|
A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results
|
FRIMPONG, JEMIMA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$378,599
|
|
Hepatitis
|
2015
|
NIAID
|
2R01AI085087-05A1
|
|
Role of Lipids in Hepatitis C Virus Maturation
|
SIDDIQUI, ALEEM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$259,625
|
|
Hepatitis
|
2015
|
NCI
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$40,495
|
|
Hepatitis
|
2015
|
NHLBI
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$28,872
|
|
Hepatitis
|
2015
|
NIA
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$5,624
|
|
Hepatitis
|
2015
|
NIAID
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$230,454
|
|
Hepatitis
|
2015
|
NICHD
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$11,249
|
|
Hepatitis
|
2015
|
NIDA
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$22,872
|
|
Hepatitis
|
2015
|
NIDDK
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$12,779
|
|
Hepatitis
|
2015
|
NIGMS
|
5P30AI045008-17
|
6413
|
Clinical Core
|
FRANK, IAN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$12,779
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK100257-03
|
|
HBV replication and persistence in mouse models
|
OU, J.-H. JAMES
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$358,785
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI079031-07
|
|
Understanding human neutralizing antibodies to hepatitis C virus
|
LAW, MANSUN
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$548,397
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA114102-09
|
|
The RB pathway in liver cancer
|
SAGE, JULIEN
|
STANFORD UNIVERSITY
|
CA
|
$278,271
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA016065-12
|
|
HCV Disease Management in HIV-HCV Coinfected IDUs
|
SULKOWSKI, MARK
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$697,750
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA031074-05
|
|
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
|
GARFEIN, RICHARD
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$568,934
|
|
Hepatitis
|
2015
|
NIDDK
|
5K23DK099422-03
|
|
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease
|
COREY, KATHLEEN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$184,691
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI069285-09
|
|
Role of TLR3 Signaling in Control of HCV
|
LI, KUI
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$337,500
|
|
Hepatitis
|
2015
|
NIAID
|
5R21AI109100-02
|
|
Damage-associated Alarmin Key to Immune Responses in Viral Hepatitis
|
SUN, JIAREN
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$193,750
|
|
Hepatitis
|
2015
|
NIDDK
|
5R42DK101240-03
|
|
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
|
KULIOPULOS, ATHAN
|
OASIS PHARMACEUTICALS
|
MA
|
$871,014
|
|
Hepatitis
|
2015
|
NIAID
|
5R21AI103838-03
|
|
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA Decay
|
GUO, HAITAO
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$195,000
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI113267-03
|
|
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
|
GUO, JU-TAO
|
BARUCH S. BLUMBERG INSTITUTE
|
PA
|
$669,728
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021912-03
|
|
Targeting DAMPs in Alcoholic Hepatitis
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$377,574
|
|
Hepatitis
|
2015
|
NIDA
|
5U01DA036267-03
|
|
MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE)
|
GORBACH, PAMINA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$1,401,419
|
|
Hepatitis
|
2015
|
NIDDK
|
5F30DK099017-03
|
|
Structure-function determination of the Hepatitis C Virus negative RNA strand's 3'-terminal sequence
|
PHAM, EDWARD
|
STANFORD UNIVERSITY
|
CA
|
$33,230
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI067417-11
|
|
Molecular Modulation of Virus Capsid Assembly
|
ZLOTNICK, ADAM
|
INDIANA UNIVERSITY BLOOMINGTON
|
IN
|
$428,479
|
|
Hepatitis
|
2015
|
OD
|
5R01OD011095-23
|
|
Modeling Viral and T Lymphocyte Dynamics
|
PERELSON, ALAN
|
LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB
|
NM
|
$435,522
|
|
Hepatitis
|
2015
|
NIAAA
|
5R01AA021133-03
|
|
RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse
|
PROESCHOLD-BELL, RAE JEAN
|
DUKE UNIVERSITY
|
NC
|
$670,501
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021908-03
|
|
Molecular Subtypes for Targeted Therapies in Alcoholic Hepatitis
|
BATALLER, RAMON
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$1,169,040
|
|
Hepatitis
|
2015
|
NIGMS
|
1SC1GM111158-01A1
|
|
Biological Studies of alpha-Hydroxytropolones
|
MURELLI, RYAN
|
BROOKLYN COLLEGE
|
NY
|
$381,100
|
|
Hepatitis
|
2015
|
NCI
|
5R21CA184920-02
|
|
(PQA 2) Obesity & Obstructive Sleep Apnea in Hepatocellular Carcinoma Progression
|
MARTINEZ, JESSE
|
UNIVERSITY OF ARIZONA
|
AZ
|
$131,805
|
|
Hepatitis
|
2015
|
NIDA
|
5R13DA022952-10
|
|
International Society for Addiction Medicine Annual Conference
|
BUNT, GREGORY
|
AMERICAN SOCIETY OF ADDICTION MEDICINE
|
MD
|
$40,000
|
|
Hepatitis
|
2015
|
NIDDK
|
5P01DK059820-14
|
5731
|
SRC-2 Mediates the Preventative Effects of LRH-1 for NASH in Metabolic Disease
|
MOORE, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$353,529
|
|
Hepatitis
|
2015
|
NIGMS
|
5R01GM081346-07
|
|
Structural basis of protein synthesis by the hepatitis C virus IRES RNA
|
KIEFT, JEFFREY
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$292,959
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7590
|
Restoration of Innate Immunity with Viral Cure
|
CHUNG, RAYMOND
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$498,302
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7591
|
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection
|
LAUER, GEORG
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$482,876
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7592
|
Epigenetic Plasticity of HCV-Specific CD8 T Cells after Antiviral Therapy
|
HAINING, WILLIAM
|
DANA-FARBER CANCER INST
|
MA
|
$414,352
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7593
|
Induction and Recovery of T Cells after Cure of Chronic Viral Infection
|
KLENERMAN, PAUL
|
UNIVERSITY OF OXFORD
|
UK
|
$250,000
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7594
|
Administrative Core
|
CHUNG, RAYMOND
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$171,977
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7595
|
Pilot/Feasibility Studies Program
|
CHUNG, RAYMOND
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$68,500
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7596
|
Tissue and Clinical Core
|
KIM, ARTHUR
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$284,557
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI082630-07
|
7597
|
Virology Core
|
ALLEN, TODD
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$106,547
|
|
Hepatitis
|
2015
|
FIC
|
5D43TW009771-02
|
|
HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.
|
MANABE, YUKARI
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$285,538
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK091601-05
|
|
Genetic determinants of NAFLD severity and progression
|
DISTEFANO, JOHANNA
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
AZ
|
$498,594
|
|
Hepatitis
|
2015
|
NIAID
|
1R01AI116639-01
|
|
Hepatitis B virus vaccine escape mutants
|
TONG, SHUPING
|
RHODE ISLAND HOSPITAL
|
RI
|
$362,250
|
|
Hepatitis
|
2015
|
NIDDK
|
1R01DK104735-01
|
|
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
|
FINCK, BRIAN
|
WASHINGTON UNIVERSITY
|
MO
|
$410,065
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI098126-04
|
|
Role of HCV in aberrant APC activation/function
|
HAHN, YOUNG
|
UNIVERSITY OF VIRGINIA
|
VA
|
$392,100
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA034086-04
|
|
Intensive Models of HCV Care for Injection Drug Users
|
LITWIN, ALAIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
NY
|
$703,813
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK044533-18
|
|
Mechanism(s) of Hepatocyte Transformation by the Hepatitis B Virus X Protein
|
ANDRISANI, OURANIA
|
PURDUE UNIVERSITY
|
IN
|
$317,018
|
|
Hepatitis
|
2015
|
NIDDK
|
1R01DK104956-01
|
|
Molecular Imaging of Liver Fibrosis
|
FUCHS, BRYAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$561,953
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021856-03
|
|
Microbiome as Therapeutic Target in Alcoholic Hepatitis
|
SCHNABL, BERND
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$414,673
|
|
Hepatitis
|
2015
|
NIAID
|
5K08AI108629-02
|
|
Interferon Effector Gene Activation to Circumvent Viral Impedance
|
FUSCO, DAHLENE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$186,192
|
|
Hepatitis
|
2015
|
NCI
|
5F31CA167872-04
|
|
Characterization of novel regulators of amino acid-sensitive mTORC1 signaling
|
SCHWEITZER, LAWRENCE
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$43,120
|
|
Hepatitis
|
2015
|
NIDA
|
5U01DA033336-03
|
|
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry
|
LEE, JOSHUA
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$672,308
|
|
Hepatitis
|
2015
|
NCI
|
1U54CA193417-01
|
7366
|
Project 1: Mechanisms of Stiffening in Liver Cancer
|
DISCHER, DENNIS
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$328,252
|
|
Hepatitis
|
2015
|
NIAAA
|
5F30AA022283-03
|
|
The Role of miR-122 in Alcoholic Liver Disease
|
SATISHCHANDRAN, ABHISHEK
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$29,567
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109662-02
|
7133
|
Haploid genetic screen to identify host genes required for RNA virruses
|
GLENN, JEFFREY
|
STANFORD UNIVERSITY
|
CA
|
$424,660
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109662-02
|
7134
|
Computation and Repurposing to identfy antivirals directed against dominant
|
PANDE, VIJAY
|
STANFORD UNIVERSITY
|
CA
|
$739,116
|
|
Hepatitis
|
2015
|
NIAID
|
5U19AI109662-02
|
7135
|
Novel Interferons and small molecule enhancers of the interferon pathway
|
GARCIA, KENAN
|
STANFORD UNIVERSITY
|
CA
|
$498,840
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021883-04
|
|
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-ADMIN)
|
CRABB, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$37,830
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI074667-07
|
|
Mechanism of Hepatitis E Virus Replication and Pathogenesis
|
MENG, XIANG-JIN
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
VA
|
$402,500
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021902-04
|
|
Novel Therapies in Alcoholic Hepatitis - UMMS Admin Core
|
SZABO, GYONGYI
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$40,618
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA033866-04
|
|
Brief intervention for drug-using rural women at high-risk for HIV/HCV
|
TINDALL, MICHELE
|
UNIVERSITY OF KENTUCKY
|
KY
|
$537,382
|
|
Hepatitis
|
2015
|
NHGRI
|
5P20HG007261-03
|
|
GUIDE: Genomic Uses in Infectious Diseases and Epidemics
|
GELLER, GAIL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$268,773
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA180083-03
|
|
(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip
|
QIN, LIDONG
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
TX
|
$521,783
|
|
Hepatitis
|
2015
|
NIMH
|
5R01MH085538-06
|
|
Hepatitis C Drives Neuropathogenesis in HIV/HCV Coinfection Patients
|
PULLIAM, LYNN
|
NORTHERN CALIFORNIA INSTITUTE/RES/EDU
|
CA
|
$508,271
|
|
Hepatitis
|
2015
|
NIDA
|
1R21DA039345-01
|
|
Facilitating HCV Treatment through Tailored Prenatal Care for HCV Infected, Substance using Pregnant Women
|
KRANS, ELIZABETH
|
MAGEE-WOMEN'S RES INST AND FOUNDATION
|
PA
|
$183,185
|
|
Hepatitis
|
2015
|
NIAID
|
1R21AI117213-01
|
|
Impact of species-specific host responses on restriction of hepatotropic viruses
|
PLOSS, ALEXANDER
|
PRINCETON UNIVERSITY
|
NJ
|
$222,688
|
|
Hepatitis
|
2015
|
NCI
|
5U01AI069919-10
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$225,000
|
|
Hepatitis
|
2015
|
NIAID
|
5U01AI069919-10
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$1,136,149
|
|
Hepatitis
|
2015
|
NICHD
|
5U01AI069919-10
|
|
IeDEA West -Africa collaboration
|
DABIS, FRANCOIS
|
ADERA
|
FR
|
$300,000
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK099226-02
|
|
G Protein pathways as Novel Therapeutic and Diagnostic Targets in Liver Fibrosis
|
GHOSH, PRADIPTA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$232,500
|
|
Hepatitis
|
2015
|
NCI
|
1R21CA188472-01A1
|
|
Racial Disparity of microRNA in Hepatitis C Virus Mediated Hepatocellularcarcinoma
|
RAY, RATNA
|
SAINT LOUIS UNIVERSITY
|
MO
|
$212,479
|
|
Hepatitis
|
2015
|
NIDDK
|
1R03DK105303-01
|
|
Hepatocyte Notch Signaling Regulates NASH
|
PAJVANI, UTPAL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$80,000
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021840-04
|
|
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
|
CRABB, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$918,831
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA033673-04
|
|
Implementation of a Sexual Health Intervention for YMSM in Two Vietnamese Cities
|
GOLDSAMT, LLOYD
|
NEW YORK UNIVERSITY
|
NY
|
$574,518
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI107301-03
|
|
Genetic viral and host adaptations to breach species barriers of HCV
|
PLOSS, ALEXANDER
|
PRINCETON UNIVERSITY
|
NJ
|
$402,500
|
|
Hepatitis
|
2015
|
NIAID
|
5R41AI112114-02
|
|
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors
|
JOHNSON, MICHAEL
|
NOVALEX THERAPEUTICS, INC.
|
IL
|
$300,000
|
|
Hepatitis
|
2015
|
NIDA
|
5U01DA036935-02
|
|
HIV Disease Outcomes in Drug Users in Clinical Practice
|
MOORE, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$1,474,110
|
|
Hepatitis
|
2015
|
NIAID
|
5K24AI108516-03
|
|
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
|
TIEN, PHYLLIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$133,824
|
|
Hepatitis
|
2015
|
NIGMS
|
5R44GM088948-03
|
|
Direct RT-PCR detection of RNA pathogens in crude samples
|
ZHANG, ZHIAN
|
DNA POLYMERASE TECHNOLOGY, INC.
|
MO
|
$416,573
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI108403-03
|
|
Antibody-Mediated Suppression of Antiviral Inflammasome Activation
|
COX, ANDREA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$442,767
|
|
Hepatitis
|
2015
|
NIAAA
|
5R01AA019976-06
|
|
Developmental pathways, environmental agents, and epigenetics in liver disease
|
ROBERTSON, KEITH
|
MAYO CLINIC ROCHESTER
|
MN
|
$576,972
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021887-05
|
|
Milk osteopontin, a nutritional therapeutic intervention for alcoholic hepatitis
|
NIETO, NATALIA
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$372,013
|
|
Hepatitis
|
2015
|
NIDDK
|
5R03DK101863-02
|
|
TLR4 in Obesity-Driven Liver Fibrosis
|
CAVIGLIA, JORGE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$200,000
|
|
Hepatitis
|
2015
|
NCI
|
5R01CA138698-06
|
|
Epidemiologic Study of Hepatocellular Carcinoma in the US
|
YU, HERBERT
|
UNIVERSITY OF HAWAII AT MANOA
|
HI
|
$1,460,631
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK061498-14
|
|
Mechanisms of Liver Injury in Nonalcoholic Fatty Liver Disease
|
CZAJA, MARK
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
NY
|
$363,225
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021907-04
|
|
Novel Therapies in alcoholic hepatitis - UMMS Translational Program
|
SZABO, GYONGYI
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$343,310
|
|
Hepatitis
|
2015
|
NIAAA
|
5U01AA021890-04
|
|
Novel therapeutics for alcoholic hepatitis - Cleveland Translational Component
|
NAGY, LAURA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
OH
|
$265,075
|
|
Hepatitis
|
2015
|
NIAID
|
5R01AI089957-05
|
|
Novel antiviral activities of tumor necrosis factor-alpha
|
DUSTIN, LYNN
|
UNIVERSITY OF OXFORD
|
UK
|
$270,000
|
|
Hepatitis
|
2015
|
NIDA
|
5R01DA036514-02
|
|
Evaluating a Microfinance Intervention for High Risk Women in Kazakhstan
|
EL-BASSEL, NABILA
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
NY
|
$702,446
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK052951-18
|
|
Genetic and molecular effects on hepatocyte nucleocytoplasm protein aggregation
|
OMARY, BISHR
|
UNIVERSITY OF MICHIGAN
|
MI
|
$387,500
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK053892-17
|
|
HNF4 Isoforms in Physiology and Disease
|
SLADEK, FRANCES
|
UNIVERSITY OF CALIFORNIA RIVERSIDE
|
CA
|
$380,000
|
|
Hepatitis
|
2015
|
NIDDK
|
5R01DK090014-05
|
|
CARD14 is essential for hepatitis C virus replication and activation of NFKB
|
TELLINGHUISEN, TIMOTHY
|
SCRIPPS FLORIDA
|
FL
|
$430,650
|
|
|
